About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diesel Exhaust and Vascular Function

NCT01508637·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Karen Jansen, M.S.
CONTACT
206-616-6525 cvd1trap@uw.edu

Lead

University of Washington

With

National Institute of Environmental Health Sciences (NIEHS)
Environmental Protection Agency (EPA)

Age

18–49

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

healthy without chronic illness
Body Mass Index 18.5 - 26.0
tolerates 2 mg terazosin dose without unacceptable symptoms
able to return for four exposure sessions

You may not be if

any chronic disease
tobacco user
asthma
elevated cholesterol
obesity
hypertension
diabetes
any chronic cardiovascular or pulmonary disease
pregnancy or unwillingness to use effective contraception, if female

The record

StatusUnknown

PhaseNo phase

Taking part24

StartedJan 2012

UpdatedAug 3, 2015

Conditions

Cardiovascular Effects

Where1

University of Washington Medical Center
Seattle, Washington, United States

Clareo Health | Diesel Exhaust and Vascular Function